Pharmacol Res 2022 04 4;178:106155. Epub 2022 Mar 4.
Traditional Chinese Medicine Resource and Technology Center, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China; Shanghai Key Laboratory for Pharmaceutical Metabolite Research, Shanghai 200433, China. Electronic address:
The XELOX chemotherapy protocol that includes capecitabine and oxaliplatin is the routine treatment for colorectal cancer (CRC), but it can cause chemotherapy-related adverse events such as thrombocytopenia (TCP). To identify predictive biomarkers and clarify the mechanism of TCP susceptibility, we conducted integrative analysis using normal colorectal tissue (CRT), plasma, and urine samples collected before CRC patients received adjuvant XELOX chemotherapy. RNA-sequencing and DNA methylation arrays were performed on CRT samples, while liquid chromatography-mass spectrometry was performed on CRT, plasma, and urine samples. Read More